Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;80(3):277-287.
doi: 10.1055/a-1111-2431. Epub 2020 Mar 4.

Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies

Andreas Schneeweiss  1 , Andreas D Hartkopf  2 , Volkmar Müller  3 , Achim Wöckel  4 , Michael P Lux  5 , Wolfgang Janni  6 , Johannes Ettl  7 , Erik Belleville  8 , Jens Huober  6 , Marc Thill  9 , Peter A Fasching  10 , Hans-Christian Kolberg  11 , Patrik Pöschke  10 , Manfred Welslau  12 , Friedrich Overkamp  13 , Hans Tesch  14 , Tanja N Fehm  15 , Diana Lüftner  16 , Florian Schütz  17
Affiliations

Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies

Andreas Schneeweiss et al. Geburtshilfe Frauenheilkd. 2020 Mar.

Abstract

This review is intended to present the latest developments in the prevention and treatment of early breast cancer. The risk of breast cancer can be increasingly better characterised with large epidemiological studies on genetic and non-genetic risk factors. Through new analyses, the evidence for high-penetrance genes as well as for low-penetrance genes was able to be improved. New data on denosumab and atezolizumab are available in the neoadjuvant situation as is a pooled appraisal of numerous studies on capecitabine in the curative situation. There is also an update to the overall survival data of pertuzumab in the adjuvant situation with a longer follow-up observation period. Finally, digital medicine is steadily finding its way into science. A recently conducted study on automated breast cancer detection using artificial intelligence establishes the basis for a future review in clinical studies.

Keywords: digital medicine; early breast cancer; immune therapy; prevention; prognosis; therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest/Interessenkonflikt A. D. H. received speaker and consultancy honoraria from AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi Sankyo, Hexal and Pfizer. F. O. received speaker and consultancy honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, Celgene, Cellex, Eisai, Gilead, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Novo Nordisk, Riemser, Roche, Servier, Shire, Tesaro, Teva. H.-C.K . received honoraria from Carl Zeiss meditec, Teva, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche, Genomic Health, Theramex, ClinSol and onkowissen.de, travel support from Carl Zeiss meditec, Novartis, Amgen, AstraZeneca, Pfizer LIV Pharma, Genomic Health, Tesaro and Daiichi Sankyo and owns stock from Theraclion and Phaon Scientific. P. A. F. received honoraria from Novartis, Pfizer, Roche, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Merck-Sharp & Dohme, Eisai, Puma and Teva. His institution conducts research with funding from Novartis and Biontech. H. T. received honoraria from Novartis, Roche, Celgene, Teva, Pfizer and travel support from Roche, Celgene and Pfizer. J. E. received honoraria from AstraZeneca, Roche, Celgene, Novartis, Lilly, Pfizer, Pierre Fabre, Teva and travel support from Celgene, Pfizer, Teva and Pierre Fabre. M. P. L. has participated on advisory boards for AstraZeneca, Lilly, MSD, Novartis, Pfizer, Eisai, Genomic Health and Roche and has received honoraria for lectures and medical education activities from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac, onkowissen.de, ClinSol and Eisai. V. M. received speaker honoraria from Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Pfizer, Novartis, Roche, Teva, Janssen-Cilag and consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi Sankyo and Eisai, Lilly, Tesaro and Nektar. E. B. received honoraria from Novartis, Hexal and onkowissen.de for consulting, clinical research management or medical education activities. A. S. received honoraria from Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH and promedicis GmbH. W. J. received honoraria and research grants from Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, Sanofi, Daichi, Tesaro. F. S. participated on advisory boards for Novartis, Lilly, Amgen and Roche and received honoraria for lectures from Roche, AstraZeneca, MSD, Novartis and Pfizer. A. W. participated on advisory boards for Novartis, Lilly, Amgen, Pfizer, Roche, Tesaro, Eisai, Celgene, Teva, Hexal, AstraZeneca, Sirtex, MSD and received honoraria for lectures from Novartis, Pfizer, Aurikamed, Roche, Amgen, Eisai, Lilly, AstraZeneca, Genomic Health, ClinSol, onkowissen.de. D. L. received honoraria from Amgen, AstraZeneca, Celgene, ClinSol, Lilly, Loreal, MSD, Novartis, onkowissen.de, Pfizer, Tesaro, Teva T. N. F. has participated on advisory boards for Amgen, Daiichi Sankyo, Novartis, Pfizer, and Roche and has received honoraria for lectures from Amgen, Celgene, Daiichi Sankyo, Roche, Novartis and Pfizer. M.T . has participated on advisory boards for AstraZeneca, Lilly, MSD, Novartis, Pfizer, Genomic Health and Roche and has received honoraria for lectures from MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, and AstraZeneca. M. W. has participated on advisory boards for AstraZeneca, Lilly, MSD, Novartis, Pfizer and Roche. J. H. reports receiving speakers bureau honoraria from Celgene, Novartis, and Roche, and is a consultant/advisory board member for Amgen, Celgene, Novartis and Roche./ A. D. H. hat Referenten- und Beraterhonorare von AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi Sankyo, Hexal und Pfizer erhalten. F. O. hat Referenten- und Beraterhonorare von Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Chugai, Celgene, Cellex, Eisai, Gilead, Hexal, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Novo Nordisk, Riemser, Roche, Servier, Shire, Tesaro und Teva erhalten. H.-C.K . hat Honorare von Carl Zeiss meditec, Teva, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche, Genomic Health, Theramex, ClinSol und onkowissen.de sowie Reiseförderungen von Carl Zeiss meditec, Novartis, Amgen, AstraZeneca, Pfizer LIV Pharma, Genomic Health, Tesaro und Daiichi Sankyo erhalten und hält Aktien von Theraclion und Phaon Scientific. P. A. F. hat Honorare von Novartis, Pfizer, Roche, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Merck-Sharp & Dohme, Eisai, Puma und Teva erhalten. Die Forschungsaktivitäten seiner Einrichtung werden finanziell von Novartis and Biontech unterstützt. H. T. hat Honorare von Novartis, Roche, Celgene, Teva und Pfizer sowie Reiseförderungen von Roche, Celgene und Pfizer erhalten. J. E. hat Honorare von AstraZeneca, Roche, Celgene, Novartis, Lilly, Pfizer, Pierre Fabre und Teva sowie Reiseförderungen von Celgene, Pfizer, Teva und Pierre Fabre erhalten. M. P. L. war Mitglied von Beratungsgremien für AstraZeneca, Lilly, MSD, Novartis, Pfizer, Eisai, Genomic Health und Roche und hat Honorare für Vorträge sowie medizinische Schulungen von MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health, AstraZeneca, medac, onkowissen.de, ClinSol und Eisai erhalten. V. M. hat Referentenhonorare von Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Pfizer, Novartis, Roche, Teva und Janssen-Cilag sowie Beraterhonorare von Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, Novartis, MSD, Daiichi Sankyo and Eisai, Lilly, Tesaro und Nektar erhalten. E. B. hat Honorare von Novartis, Hexal und onkowissen.de für Beratungstätigkeiten, die Leitung klinischer Forschungsvorhaben bzw. medizinische Schulungen erhalten. A. S. hat Honorare von Roche, Celgene, AstraZeneca, Novartis, Pfizer, Zuckschwerdt Verlag GmbH, Georg Thieme Verlag, Aurikamed GmbH, MCI Deutschland GmbH, bsh medical communications GmbH und promedicis GmbH erhalten. W. J. hat Honorare und Forschungsstipendien von Novartis, Roche, Pfizer, Lilly, AstraZeneca, Chugai, Sanofi, Daichi und Tesaro erhalten. F. S. war Mitglied von Beratungsgremien für Novartis, Lilly, Amgen und Roche und hat Vortragshonorare von Roche, AstraZeneca, MSD, Novartis und Pfizer erhalten. A. W. war Mitglied von Beratungsgremien für Novartis, Lilly, Amgen, Pfizer, Roche, Tesaro, Eisai, Celgene, Teva, Hexal, AstraZeneca, Sirtex und MSD und hat Vortragshonorare von Novartis, Pfizer, Aurikamed, Roche, Amgen, Eisai, Lilly, AstraZeneca, Genomic Health, ClinSol und onkowissen.de erhalten. D. L. hat Honorare von Amgen, AstraZeneca, Celgene, ClinSol, Lilly, Loreal, MSD, Novartis, onkowissen.de, Pfizer, Tesaro und Teva erhalten. T. N. F. war Mitglied von Beratungsgremien für Amgen, Daiichi Sankyo, Novartis, Pfizer und Roche und hat Vortragshonorare von Amgen, Celgene, Daiichi Sankyo, Roche, Novartis und Pfizer erhalten. M.T . war Mitglied von Beratungsgremien für AstraZeneca, Lilly, MSD, Novartis, Pfizer, Genomic Health und Roche und hat Vortragshonorare von MSD, Lilly, Roche, Novartis, Pfizer, Genomic Health und AstraZeneca erhalten. M. W. war Mitglied von Beratungsgremien für AstraZeneca, Lilly, MSD, Novartis, Pfizer und Roche. J. H. gibt an, Referentenvermittlungshonorare von Celgene, Novartis und Roche zu erhalten und ist Berater/Mitglied von Beratungsgremien für Amgen, Celgene, Novartis und Roche.

Figures

Fig. 1
Fig. 1
Overall survival for patients in the OLympiaD study without previous therapies (printed under the Creative Commons Attribution Non-Commercial License from 10 ).
Fig. 2
Fig. 2
Design of the GeparX study. GeparX is a multicentre, prospective, 2 × 2 randomised, open phase IIb study to compare a neoadjuvant chemotherapy with and without denosumab in patients with untreated breast cancer.
Fig. 3
Fig. 3
Design of the cbcsg010 study (Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer, NCT01642771). [rerif]
Abb. 1
Abb. 1
Gesamtüberleben für Patientinnen in der OLympiaD-Studie ohne vorherige Vortherapien (abgedruckt unter der Creative Commons Attribution Non-Commercial License aus 10 ).
Abb. 2
Abb. 2
Design der GeparX-Studie. GeparX ist eine multizentrische, prospektive, 2 × 2 randomisierte, offene Phase-IIb-Studie zum Vergleich einer neoadjuvanten Chemotherapie mit und ohne Denosumab bei Patientinnen mit unbehandeltem Brustkrebs.
Abb. 3
Abb. 3
Design der cbcsg010-Studie (Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer, NCT01642771). [rerif]
See this image and copyright information in PMC

References

    1. Ditsch N, Untch M, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019;14:224–245. - PMC - PubMed
    1. Thill M, Jackisch C, Janni W. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel) 2019;14:247–255. - PMC - PubMed
    1. Welslau M, Hartkopf A D, Muller V. Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtsh Frauenheilk. 2019;79:1090–1099. - PMC - PubMed
    1. Schutz F, Fasching P A, Welslau M. Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtsh Frauenheilk. 2019;79:1079–1089. - PMC - PubMed
    1. Kolberg H C, Schneeweiss A, Fehm T N. Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtsh Frauenheilk. 2019;79:470–482. - PMC - PubMed